Filing Flows › Neogenomics (NEO) › Q4 2025
Neogenomics (NEO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 17, 2026
Neogenomics (NEO) reported revenue of $190M for the fourth quarter 2025 (Q4 2025), +11% from a year earlier and +1% from the quarter before. Operating margin was -7.1%, net loss $9.9M (5.2% of revenue).
Neogenomics, Q4 2025: revenue $190M (+11% year over year), operating margin -7.1%, net loss $9.9M, operating cash flow $1.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $190M | +1% | +11% |
| Operating profit | −$13.4M | — | — |
| Net earnings | −$9.9M | — | — |
| Operating cash flow | $1.3M | -85% | -86% |
What changed
Revenue was $190.2M in Q4 2025, up 11% year over year and up 1% from the previous quarter. Client direct billing was the largest line at 70% of revenue.
Gross margin was 43.8%, down 1.1 points from a year earlier. Operating costs exceeded revenue by $13.4M, an operating margin of -7.1%. Operating expenses grew 1% against revenue growth of 11%. The fastest-growing cost line was Research & development (+15%). The quarter ended with a net loss of $9.9M, narrower than the previous quarter's $27.1M loss.
Operating cash flow was $1.3M (down 86% year over year). Non-cash charges added back $16.4M of depreciation and amortization and $8.0M of share-based compensation. Working capital and other items used $13.2M. Capital expenditures of $7.9M exceeded it, leaving free cash flow of −$6.5M.
Questions
What was Neogenomics' revenue in the fourth quarter 2025?
Neogenomics (NEO) reported revenue of $190M for the fourth quarter 2025 (Q4 2025), +11% from a year earlier and +1% from the quarter before.
Was Neogenomics profitable in the fourth quarter 2025?
Operating loss was $13.4M (-7.1% of revenue) and net loss $9.9M.
Source: Neogenomics 10-K on SEC EDGAR.